Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Esperion Therapeutics, Inc.
With
Medpace, Inc.
Approximately 132 hypercholesterolemic patients already taking statin therapy to treat elevated LDL-C will be randomized in a ratio of 1:1:1 to receive either ETC-1002 (120 mg or 180 mg dose), or placebo for 12 weeks in addition to ongoing statin therapy. This study will explore the safety and efficacy of ETC-1002 when given to patients receiving statin therapy.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Fasting, calculated mean LDL-C ≥130 mg/dL and ≤220 mg/dL
Fasting mean TG level ≤400 mg/dL
Stable statin therapy for at least 3 months prior to screening: atorvastatin (10 or 20 mg daily), simvastatin (5, 10 or 20 mg daily), rosuvastatin (5 or 10 mg daily), or pravastatin (10, 20 or 40 mg daily)
You may not be if
Clinically significant cardiovascular disease within 12 months of screening
Current muscle-related symptoms that may be due to ongoing statin therapy or a history of certain lab abnormalities that occurred during statin therapy and resolved when statin therapy was discontinued
Type 1 diabetes or uncontrolled type 2 diabetes
Use of metformin or thiazolidinediones (TZD) within 4 weeks of screening
History of chronic musculoskeletal symptoms such as fibromyalgia
Uncontrolled hypothyroidism
Liver disease or dysfunction
Renal dysfunction or nephritic syndrome
Gastrointestinal conditions or procedures or surgeries
Hematologic or coagulation disorders or low hemoglobin levels
HIV or AIDS
History of malignancy
History of drug or alcohol abuse within 2 years
Use of experimental or investigational drugs within 30 days of screening